Literature DB >> 32558351

Hypercoagulability (thrombin generation) in patients with cirrhosis is detected with ST-Genesia.

Laurie Talon1, Thomas Sinegre1, Thomas Lecompte2, Bruno Pereira3, Sylvie Massoulié4, Armand Abergel4, Aurélien Lebreton1.   

Abstract

BACKGROUND: Thrombin generation assays (TGAs) performed with calibrated automated thrombography (CAT) in the presence of thrombomodulin (TM) indicate plasma hypercoagulability in cirrhosis.
OBJECTIVE: To evaluate, in the presence of TM, the new ST-Genesia automated device developed for improving TGA vs the previously used CAT method, with plasma samples of patients with cirrhosis. PATIENTS/
METHODS: Platelet-poor plasma samples were prepared from citrated blood samples of 52 healthy controls and 85 patients with cirrhosis (severity evaluated using the Child-Pugh score [CP]). TGAs were performed using CAT with PPP-Reagent and ST-Genesia with the STG-ThromboScreen reagent, in the presence of TM. Endogenous thrombin potential (ETP) was chosen as the main parameter.
RESULTS: Whatever the method, ETP values were higher in patients than in healthy controls. All patients identified as hypercoagulable with ST-Genesia and STG-ThromboScreen were found hypercoagulable with CAT and PPP-Reagent. Conversely, eight and ten patients in the CP-A and CP-B classes respectively were identified as hypercoagulable only with CAT. The use of ST-Genesia with the STG-ThromboScreen reagent with TM led to a bias, with higher ETP values for healthy controls and lower for patients compared with CAT. Crossover analysis (CAT with the STG-ThromboScreen reagent) evidenced a substantial effect of the STG-ThromboScreen reagent; the analyzer (including calibration and data analysis) plays a lesser role.
CONCLUSION: ST-Genesia evidences hypercoagulability in patients with cirrhosis when TG is studied in the presence of TM, but the results are not interchangeable with those obtained with CAT.
© 2020 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  blood coagulation; blood coagulation test; clinical laboratory techniques; liver cirrhosis; thrombomodulin

Mesh:

Substances:

Year:  2020        PMID: 32558351     DOI: 10.1111/jth.14963

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  5 in total

1.  Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence.

Authors:  Patricia Gomez-Rosas; Marina Pesenti; Cristina Verzeroli; Cinzia Giaccherini; Laura Russo; Roberta Sarmiento; Giovanna Masci; Luigi Celio; Mauro Minelli; Sara Gamba; Carmen Julia Tartari; Carlo Tondini; Francesco Giuliani; Fausto Petrelli; Andrea D'Alessio; Giampietro Gasparini; Roberto Labianca; Armando Santoro; Filippo De Braud; Marina Marchetti; Anna Falanga
Journal:  TH Open       Date:  2021-02-10

2.  Anticoagulated patients exhibit intact endogenous thrombin potential using ST Genesia unlike the Calibrated Automated Thrombogram.

Authors:  Tuukka A Helin; Marja Lemponen; Riitta Lassila; Lotta Joutsi-Korhonen
Journal:  Res Pract Thromb Haemost       Date:  2021-03-11

3.  Comparison of Acquired Activated Protein C Resistance, Using the CAT and ST-Genesia® Analysers and Three Thrombin Generation Methods, in APS and SLE Patients.

Authors:  Maria Efthymiou; Philip J Lane; David Isenberg; Hannah Cohen; Ian J Mackie
Journal:  J Clin Med       Date:  2021-12-23       Impact factor: 4.241

4.  Analytical performance of the endogenous thrombin potential-based activated protein C resistance assay on the automated ST Genesia system.

Authors:  Laure Morimont; Charline Leclercq; Marie Didembourg; Émilie De Gottal; Audrey Carlo; Ulysse Gaspard; Jean-Michel Dogné; Jonathan Douxfils
Journal:  Res Pract Thromb Haemost       Date:  2022-04-07

5.  Assessing the individual roles of FII, FV, and FX activity in the thrombin generation process.

Authors:  Cuicui Bai; Joke Konings; Marisa Ninivaggi; Marcus Lancé; Bas de Laat; Romy de Laat-Kremers
Journal:  Front Cardiovasc Med       Date:  2022-09-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.